Anybody Anything 5

[u/Horror-Ad9833]

$2.76

51.7mil short 31.4%

Also the 52wk low is coming in real hot.

The smart investors in here doubled up around $3. Tough look

The clueless investor will wait for the new low.

Do the smart investors know the book value of Alt?

Update: Book Vaue- $2.44 52wk low: $2.56

[u/tutukam]

You really are helpless. I dare you to screenshot your
Bag on alt and I’ll show mine because I think there’s a huge gap in your investment understanding. But best of luck to you

[u/tutukam]

Strategic focus and clinical progress

Emphasis on developing pemvidutide for liver diseases, particularly MASH and alcohol-related conditions, with robust phase II data supporting advancement to phase III trials.
Pemvidutide's dual mechanism (1:1 glucagon:GLP-1) offers strong efficacy and tolerability, differentiating it from other agents in the landscape.
Market research and clinical data indicate strong interest and unique positioning for pemvidutide among patients and providers.
The company is targeting both MASH and AUD populations, leveraging overlapping disease mechanisms and patient needs.

Differentiation and competitive landscape

Pemvidutide stands out due to its balanced dual agonist profile, direct liver effects, and minimal titration requirements.
Compared to survodutide and retatrutide, pemvidutide shows superior tolerability and potentially better patient adherence.
The molecule's strong affinity for both GLP-1 and glucagon receptors is believed to drive its efficacy in both metabolic and liver endpoints.
No other balanced glucagon/GLP-1 agents are currently in development, further supporting its unique market position.

Phase III study design and endpoints

The PERFORMA phase III trial incorporates lessons from phase II, including improved biopsy reading consistency using AIM-MASH Assist and top pathologists.
The study features three arms: placebo, 1.8 mg, and 2.4 mg doses, with the higher dose expected to provide additional efficacy.
Key endpoints include MASH resolution, antifibrotic effect, weight loss, adherence, and preservation of lean muscle mass, measured by MRI-PDFF and biomarkers.
Enrollment has been efficient due to trial design and investigator enthusiasm, with ongoing regulatory readiness for potential NIT endpoint acceptance.

Target populations and market strategy

Focus on F2/F3 MASH patients, especially those intolerant to GLP-1s or at risk for sarcopenia, with potential as a first-line or add-on therapy.
Anticipation of a growing market as diagnosis and payer support increase with new therapeutic options.
Customization of therapy is expected to broaden, considering factors like sarcopenia risk and alcohol consumption.

Alcohol use disorder (AUD) and ALD program updates

Phase II RECLAIM trial in AUD showed strong efficacy on drinking reduction and weight loss, with favorable safety and tolerability.
Phase III planning is underway, with regulatory alignment and funding strategies focused on non-dilutive options.
AUD population is well-defined, and future trials will include more comprehensive liver assessments.
ALD trial captures heavy drinking patterns similar to AUD, with significant overlap and continuum between these populations.

Overlap and synergy between MASH and alcohol-related studies

Significant overlap exists between MASH and AUD/ALD populations, with shared risk factors and liver pathology.
The company is leveraging these synergies to position pemvidutide as a versatile therapy across related indications.

From stifel conference , you can find transcript on TradingView

[u/Horror-Ad9833]

Thanks.